Presenting our prostate cancer research at two international meetings

Mari Bogaard at the 34th European Congress of Pathology in Basel, Switzerland (photo: Ulrika Axcrona)
Mari Bogaard at the 34th European Congress of Pathology in Basel, Switzerland (photo: Ulrika Axcrona)

Our prostate cancer projects received attention and interest at the recent Norwegian Cancer Symposium held in Oslo and at the 34th European Congress of Pathology held in Basel, Switzerland.

Mari Bogaard (first author) was awarded the "third best poster prize" at the 34th European Congress of Pathology for the work: "GRIN3A – a novel biomarker identifying a subtype of intraductal prostate cancer". The congress was organized by the European Society of Pathology and held as a hybrid congress, with more than 4200 participants from 100 countries in attendance either in person or virtually, and with 177 live sessions and 1402 submitted abstracts. Mari has Ulrika Axcrona as main supervisor and performs her molecular work in the group of Rolf Skotheim.

The Norwegian Cancer Symposium 2022, sponsored by Norsk Hydro, was this year entitled "Sustainable cancer care using molecular tests - From a prostate cancer perspective". The Symposium was held 14-15th September at Clarion hotel, Oslo, and had 130 delegates and 17 invited speakers, from 11 countries, representing academia and industry. Rolf Skotheim was member of the Organizing committee. Research projects affiliated to the Skotheim and Axcrona groups were presented as two oral and three poster presentations.

Oral presentations

Ulrika Axcrona et al. Cribriform growth pattern with a high Ki-67 represents a subgroup of prostate cancer patients with a particularly poor prognosis (selected from submitted abstract).

Rolf Skotheim. Multifocal prostate cancer and implications for precision oncology.

Poster presentations

Mari Bogaard et al., GRIN3A – a novel biomarker identifying a subtype of intraductal prostate cancer.

Susanne Kidd et al., In situ expression of ERG protein in the context of tumour heterogeneity identifies prostate cancer patients with inferior prognosis.

Bjarne Johannessen et al., Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer.

 
Page visits: 151